Leo Pharma receives EU approval for Enstilar

Leo Pharma has announced that its new psoriasis therapy Enstilar has been approved in Europe.

The alcohol-free foam formulation for the topical treatment for psoriasis vulgaris has been ratified for use in patients over the age of 18, based on positive data from the phase IIIa trial PSO-FAST.

This study evaluated the product's efficacy and safety profile across a four-week period, showing that more than half of patients treated with Enstilar were clear or almost clear of their symptoms by the end of the month.

Psoriasis vulgaris is the most common clinical form of psoriasis, a condition that affects around four million people in Europe.

Gitte Aabo, president and chief executive officer of Leo Pharma, said: "Enstilar is a first-of-its-kind topical spray foam and we believe it will help people living with psoriasis by providing a new type of treatment option that they are looking for."

This comes after Michael Hinchy was hired as the company's new dermatology director with responsibility for its UK and Ireland business earlier this month.